PFE starts phase-3 for Prevnar-20—the successor to Prevar-13 with (claimed) protection against seven additional pneumococcal strains: https://finance.yahoo.com/news/pfizer-initiates-phase-3-program-130000290.html Prevnar-20 has FDA BTD status (#msg-143693098). Prevnar is one of PFE’s most commercially important franchises.